Adaptive Biotechnologies

Learn more about the data

Read the press release

ImmuneCODE™ Launched

De-identified COVID-19 immune response data available to help accelerate solutions to the pandemic

1,641,264,689 TCRs Sequenced

6,552 Samples

Learn more

Read our press release

clonoSEQ® is now FDA-cleared
for MRD assessment in patients with Chronic Lymphocytic Leukemia (CLL).

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Learn more

Read the press release

Now providing you the powerful tools you need to fully understand the T-cell response in COVID-19

NOW AVAILABLE

For Research Use Only. Not for use in diagnostic procedures.

Learn more

Developing Therapeutic Antibodies Against COVID-19

Every immune system has a story to tell.

The key is knowing how to listen.

At Adaptive, we’re writing the next chapter of precision health — powered by immune-driven medicine.

OUR STORY

Pioneers in immune-driven medicine

Our goal is to meaningfully improve people’s lives by learning from the wisdom of their adaptive immune systems. It’s a bold objective that we’re uniquely built to achieve.